Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glaucoma therapy · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Glaucoma therapy | DRUG | - |
Inclusion Criteria: * Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension; * logMAR visual acuity not worse than 0.6. Exclusion Criteria: * Clinically relevant ophthalmic or systemic conditions may be excluded.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
Glaucoma therapy is an investigational small molecule being developed by Alcon Inc. for the treatment of Open-Angle Glaucoma. It is also being studied in patients with Ocular Hypertension. The therapy is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Glaucoma therapy is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. The therapy is in Phase 2 clinical development for the treatment of Open-Angle Glaucoma and Ocular Hypertension.
Glaucoma therapy is in Phase 2 clinical development. It is an investigational small molecule being studied for the treatment of Open-Angle Glaucoma and Ocular Hypertension. The therapy has not been approved and remains in clinical testing.
Glaucoma therapy has one completed clinical trial, NCT00069719, a Phase II safety and efficacy study conducted in the United States. The study evaluated the therapy in patients with Open-Angle Glaucoma or Ocular Hypertension, enrolled adults aged 18 years and older, and was randomized and double-blind.
Glaucoma therapy is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Open-Angle Glaucoma and Ocular Hypertension. The therapy has completed one clinical trial, but it remains under investigation and has not received regulatory approval.